Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sildenafil in Children with Pulmonary Arterial Hypertension (STARTS-1)
NCT00159913Phase 3Completed
- Sponsor
- Viatris
- Start
- Aug 2003
- Primary completion
- Jun 2008
- Modality
- Small Molecules
- Countries
- 17
01
Overview
Phase 3, randomised, double-blind trial of ASP-001 in pulmonary arterial hypertension (PAH) (4 arms), sponsored by Viatris. Primary endpoint: Percent Change From Baseline in Peak Volume of Oxygen (VO2) Consumed at 16 weeks. Started Aug 2003; status: completed.
02
Drugs
ASP-001
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT00159913.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00159913.